Braidwell’s Soleno Therapeutics SLNO Stock Holding History

Braidwell’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-959,259	Closed	-$32.1M	–	106
2026 Q1	$32.1M	Sell	959,259 -228,600	-19%	-$8.96M	1.07%	36
2025 Q4	$55M	Sell	1,187,859 -94,130	-7%	-$5.16M	1.76%	15
2025 Q3	$86.7M	Buy	+1,281,989	New	+$95M	2.57%	11

Braidwell's SLNO Position: Q2 2026 in Review

Braidwell sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 959,259 shares — an estimated $32.1M sold.

Braidwell first reported a position in SLNO in Q3 2025 and held it in 3 quarters. The position peaked at $86.7M in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Braidwell reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Braidwell sold 959,259 Soleno Therapeutics shares in Q2 2026, an estimated $32.1M.
Braidwell first reported a position in Soleno Therapeutics in Q3 2025 and held it in 3 quarters.
Braidwell's Soleno Therapeutics position peaked at $86.7M in Q3 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.